Association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy

International Journal of Urology

Volumn 19, Issue 8, 2012, Pages 741-747

  Moreira, Daniel M ^a,c   Gerber, Leah ^a,c   Thomas, Jean Alfred ^a,c   Bañez, Lionel L ^a,c   Mckeever, Madeline G ^a,c   Freedland, Stephen J ^a,b,c  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Biopsy; Diagnosis; Kinetics; Pathology; Prostate specific antigen; Prostatic neoplasm

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; CANCER GRADING; CANCER RISK; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN DOUBLING TIME; RACE DIFFERENCE; REPEAT PROCEDURE;

AGED; BIOPSY; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84864319632     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03016.x     Document Type: Article

References (23)

1. Djavan B, Mazal P, Zlotta A etal. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study. Prostate 2001; 47: 111-17.
2. Singh H, Canto EI, Shariat SF etal. Predictors of prostate cancer after initial negative systematic 12 core biopsy. J. Urol. 2004; 171: 1850-4.
3. Busby JE, Evans CP. Determining variables for repeat prostate biopsy. Prostate Cancer Prostatic Dis. 2004; 7: 93-8.
4. Sakura M, Kawakami S, Ishioka J etal. A novel repeat biopsy nomogram based on three-dimensional extended biopsy. Urology 2011; 77: 915-20.
5. Andriole GL, Bostwick DG, Brawley OW etal. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 2010; 362: 1192-202.
6. Eastham JA. Prostate-specific antigen doubling time as a prognostic marker in prostate cancer. Nat. Clin. Pract. Urol. 2005; 2: 482-91.
7. Perlmutter MA, Lepor H. Prostate-specific antigen doubling time is a reliable predictor of imageable metastases in men with biochemical recurrence after radical retropubic prostatectomy. Urology 2008; 71: 501-5.
8. Freedland SJ, Humphreys EB, Mangold LA etal. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-9.
9. Freedland SJ, Humphreys EB, Mangold LA etal. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J. Clin. Oncol. 2007; 25: 1765-71.
10. Shimbo M, Tomioka S, Sasaki M etal. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer. Jpn. J. Clin. Oncol. 2009; 39: 727-31.
11. Thompson IM, Ankerst DP, Chi C etal. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J. Natl. Cancer Inst. 2006; 98: 529-34.
12. Welch HG, Black WC. Overdiagnosis in cancer. J. Natl. Cancer Inst. 2010; 102: 605-13.
13. Ross AE, Loeb S, Landis P etal. Prostate-Specific Antigen Kinetics During Follow-Up Are an Unreliable Trigger for Intervention in a Prostate Cancer Surveillance Program. J. Clin. Oncol. 2010; 28: 2810-16.
14. Krakowsky Y, Loblaw A, Klotz L. Prostate Cancer Death of Men Treated With Initial Active Surveillance: clinical and Biochemical Characteristics. J. Urol. 2010; 184: 131-5.
15. Stephenson AJ, Aprikian AG, Souhami L etal. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 2002; 59: 652-6.
16. Ng MK, Van As N, Thomas K etal. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time. BJU Int. 2009; 103: 872-6.
17. Catalona WJ, Partin AW, Slawin KM etal. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542-7.
18. Carter HB, Pearson JD, Metter EJ etal. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-20.
19. Djavan B, Remzi M, Schulman CC, Marberger M, Zlotta AR. Repeatprostate biopsy: who, how and when? A review. Eur. Urol. 2002; 42: 93-103.
20. Moussa AS, Jones JS, Yu C, Fareed K, Kattan MW. Development and validation of a nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session in the era of extended prostate sampling. BJU Int. 2010; 106: 1309-14.
21. Roobol MJ, Steyerberg EW, Kranse R etal. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur. Urol. 2010; 57: 79-85.
22. Xu J, Zheng SL, Isaacs SD etal. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 2010; 107: 2136-40.
23. Sartor AO, Hricak H, Wheeler TM etal. Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology 2008; 72: S12-24.